Improving Response Inhibition in Parkinson’s Disease with Atomoxetine

BACKGROUND: Dopaminergic drugs remain the mainstay of Parkinson’s disease therapy but often fail to improve cognitive problems such as impulsivity. This may be due to the loss of other neurotransmitters, including noradrenaline, which is linked to impulsivity and response inhibition. We therefore ex...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biol Psychiatry
Hauptverfasser: Ye, Zheng, Altena, Ellemarije, Nombela, Cristina, Housden, Charlotte R., Maxwell, Helen, Rittman, Timothy, Huddleston, Chelan, Rae, Charlotte L., Regenthal, Ralf, Sahakian, Barbara J., Barker, Roger A., Robbins, Trevor W., Rowe, James B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2015
Schlagworte:
Archival Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4384955/
https://ncbi.nlm.nih.gov/pubmed/24655598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biopsych.2014.01.024
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge